新诺威(300765.SZ)：控股子公司SYS6090注射液获得药物临床试验批准通知书

Core Viewpoint - XinNuoWei (300765.SZ) announced that its subsidiary, Giant Stone Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of SYS6090 injection, which will commence shortly [1] Group 1: Product Details - SYS6090 injection is a recombinant fully human anti-PD-1 fusion protein with IL-15, designed as an asymmetric structure dual-functional Fc, which aims to weaken Fc-mediated immune functions [1] - The left arm of SYS6090 targets PD-1 positive tumor-infiltrating immune cells to block the immunosuppressive interaction between PD-1 and PD-L1 [1] - The right arm binds to the IL-15 receptor, activating downstream signaling pathways to further promote the activation and proliferation of relevant immune cells [1] Group 2: Preclinical Research Findings - Preclinical studies have shown that SYS6090 injection significantly inhibits tumor growth and demonstrates good safety and tolerability [1] - Compared to other PD-1 monoclonal antibodies and IL-15 drugs, SYS6090 exhibits higher efficacy [1]